Cellectar Biosciences Gestione

Gestione criteri di controllo 2/4

Cellectar Biosciences Il CEO è Jim Caruso, nominato in Jun2015, e ha un mandato di 9.42 anni. la retribuzione annua totale è $ 1.97M, composta da 30.5% di stipendio e 69.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.14% delle azioni della società, per un valore di $ 88.00K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 8.5 anni.

Informazioni chiave

Jim Caruso

Amministratore delegato

US$2.0m

Compenso totale

Percentuale dello stipendio del CEO	30.5%
Mandato del CEO	9.4yrs
Proprietà del CEO	0.1%
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	8.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Aug 08

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

Feb 12

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Aug 23

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Oct 05

Cellectar shares fall after mid-stage CLR 131 trial data fails to impress

Jun 04

We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

May 20

Cellectar Biosciences EPS beats by $0.03

May 10

Cellectar gets notification of formal grant from Australian and Mexican patent authorities

Apr 27

Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer

Jan 12

Cellectar Bio readies stock offering

Dec 23

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Nov 30

Cellectar Biosciences EPS beats by $0.05

Nov 09

Cellectar Bio's lead asset shows encouraging action in early-stage study of pediatric tumors

Nov 05

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jim Caruso rispetto agli utili di Cellectar Biosciences?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$50m
Jun 30 2024	n/a	n/a	-US$53m
Mar 31 2024	n/a	n/a	-US$62m
Dec 31 2023	US$2m	US$600k	-US$43m
Sep 30 2023	n/a	n/a	-US$42m
Jun 30 2023	n/a	n/a	-US$36m
Mar 31 2023	n/a	n/a	-US$33m
Dec 31 2022	US$1m	US$569k	-US$32m
Sep 30 2022	n/a	n/a	-US$27m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$2m	US$523k	-US$24m
Sep 30 2021	n/a	n/a	-US$22m
Jun 30 2021	n/a	n/a	-US$20m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$1m	US$475k	-US$15m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$934k	US$451k	-US$14m
Sep 30 2019	n/a	n/a	-US$15m
Jun 30 2019	n/a	n/a	-US$16m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$770k	US$425k	-US$15m
Sep 30 2018	n/a	n/a	-US$17m
Jun 30 2018	n/a	n/a	-US$15m
Mar 31 2018	n/a	n/a	-US$16m
Dec 31 2017	US$994k	US$410k	-US$15m

Compensazione vs Mercato: La retribuzione totale di Jim ($USD 1.97M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 649.63K ).

Compensazione vs guadagni: La retribuzione di Jim è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Jim Caruso (65 yo)

9.4yrs

Mandato

US$1,965,140

Compensazione

Mr. James V. Caruso, also known as Jim, is Member of Advisory Board & Director of Hip Innovation Technology, LLC. Mr. Caruso has been the Chief Executive Officer and President of Cellectar Biosciences, Inc...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
James Caruso	President	9.4yrs	US$1.97m	0.14% $ 88.0k
Chad Kolean	VP, CFO & Secretary	2.8yrs	US$1.11m	0.12% $ 76.1k
Jarrod Longcor	Chief Operating Officer	2.8yrs	US$1.36m	0.15% $ 95.0k
Darrell Lea	Chief Commercial Officer	2yrs	Nessun dato	0.11% $ 70.8k
Andrei Shustov	Senior Vice President of Medical	1.8yrs	Nessun dato	0.15% $ 98.4k

2.8yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di CLRB è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
James Caruso	President	9.4yrs	US$1.97m	0.14% $ 88.0k
John Neis	Independent Director	16.8yrs	US$93.25k	0.017% $ 11.2k
Frederick Driscoll	Independent Director	7.6yrs	US$93.25k	0.0054% $ 3.5k
Stefan Loren	Independent Director	9.4yrs	US$93.25k	0% $ 0
Douglas Swirsky	Independent Chairman of the Board	7.6yrs	US$109.88k	0.0070% $ 4.5k
Asher Chanan-Khan	Independent Director	3.4yrs	US$48.25k	0% $ 0

8.5yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CLRB sono considerati esperti (durata media dell'incarico 8.5 anni).

Cellectar Biosciences Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

Cellectar Biosciences, Inc., Annual General Meeting, Jun 14, 2024

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical

Cellectar Biosciences, Inc. Announces Appointment of Shane Lea as Chief Commercial Officer

Cellectar Biosciences, Inc., Annual General Meeting, Jun 15, 2022

Cellectar Biosciences Appoints Jarrod Longcor as Chief Operating Officer

Recent updates

Cellectar Biosciences, Inc. announced delayed 10-Q filing

Cellectar Biosciences, Inc. to Report Q3, 2024 Results on Nov 18, 2024

Cellectar Biosciences, Inc. to Present New Data from Phase 2 CLOVER -WaM Study in Oral Session at ASH 2024

Cellectar Biosciences Regains Compliance with Nasdaq Listing Rule 5250(c)(1) Regarding Filing of Form 10-Q

Cellectar Biosciences Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Cellectar Biosciences, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Cellectar Biosciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Cellectar Biosciences, Inc. Announces Positive Results Data from its Ongoing CLover WaM Pivotal Study Evaluating Iopofosine I 131 for the Treatment of Relapsed/Refractory Waldenstrom's Macroglobulinemia

Insufficient new directors

Cellectar Biosciences, Inc. to Report Q1, 2024 Results on May 14, 2024

Cellectar Biosciences, Inc., Annual General Meeting, Jun 14, 2024

New minor risk - Market cap size

New major risk - Financial position

Price target increased by 23% to US$14.75

Cellectar Biosciences, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

New major risk - Shareholder dilution

Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study

Cellectar Biosciences, Inc. Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

Forecast to breakeven in 2026

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia

Forecast to breakeven in 2026

New minor risk - Profitability

Cellectar Biosciences, Inc. announced that it has received $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc.

Nasdaq Grants Cellectar Biosciences an Extension to Take Action to Evidence Compliance with Nasdaq Listing Rule 5550(b), on or Before January 4, 2024

Cellectar Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cellectar Biosciences, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia

Price target decreased by 7.7% to US$12.00

Cellectar Biosciences, Inc. announced that it expects to receive $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc. and other investors

Cellectar Biosciences Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

New major risk - Negative shareholders equity

New minor risk - Share price stability

Cellectar Biosciences, Inc. Provides an Update for Its iopofosine I 131 Clinical Program and Guidance Related to Its Proprietary Phospholipidether Drug Conjugate Platform

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical

Cellectar Biosciences, Inc. Announces Appointment of Shane Lea as Chief Commercial Officer

Cellectar Biosciences, Inc. Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference

Cellectar Biosciences, Inc. Announces Resolution of Breach of Contract and Intellectual Property Dispute

Price target decreased to US$12.60

Price target decreased to US$33.63

Cellectar Biosciences, Inc. announced that it has received $3.911327 million in funding

Cellectar Biosciences, Inc. Wins $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors

Cellectar Biosciences, Inc. Announces Publication of Data from its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19

Price target decreased to US$39.38

Cellectar announces reverse stock split

Price target increased to US$5.88

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Nasdaq Grants Extension to Cellectar Biosciences Until October 31, 2022 to Regain Compliance

Cellectar Biosciences, Inc., Annual General Meeting, Jun 15, 2022

Cellectar Biosciences Appoints Jarrod Longcor as Chief Operating Officer

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?

Cellectar Biosciences, Inc. Presents Data from Its Ongoing Phase 2 Clover-1 Study of Iopofosine I-131 At the 63rd Ash Annual Meeting and Exposition

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Cellectar Biosciences, Inc. Announces the Completion of the Part A Portion of A Safety and Tolerability Study of Iopofosine I-131 (Iopofosine) in Combination with External Beam Radiation (Ebrt) in Relapsed or Refractory Head and Neck Cancer

Price target decreased to US$5.38

High number of new directors

Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster At the 2021 American Society of Clinical Oncology Annual Meeting

Cellectar shares fall after mid-stage CLR 131 trial data fails to impress

We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

Cellectar Biosciences EPS beats by $0.03

Cellectar Biosciences, Inc. Receives Notification of Formal Grant of the Patent Titled Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles by the Eurasian, Australian and Mexican Patent Authorities

Cellectar gets notification of formal grant from Australian and Mexican patent authorities

Cellectar Biosciences, Inc. Announces Japan Patent Office Granted Patent, Titled, 'Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles'

New 90-day low: US$1.74